This study aims to explore whether pre-operative or post-operative percentages of circulating myeloid-derived suppressor cells (MDSC) have any correlations with clinicopathological parameters in patients with rectal cancer and have any predictive values for local recurrence and disease free survival. Lin -/HLADR -/CD11b + /CD33 + MDSCs were analyzed in the study. Blood samples before and after surgery were measured by flow cytometry to determine the MDSC percentages. Plasma arginase I levels were analyzed using an enzyme-linked immunosorbent assay. Digital rectal examination, abdominal ultrasonography, or computed tomography was performed every three months after surgery to monitor local recurrence. Prior to surgery, cancer patients presented with higher levels of circulating MDSC compared to healthy controls (medians of 3.89% and 0.57%, respectively). Seven days after operation, we observed an immediate increase in MDSC followed by a downtrend. Local recurrence was observed in 11 of 41 patients (26.8%) with stage I/II cancer and 11 of 23 patients (47.8%) with stage III cancer. Significantly higher percentages of MDSC were observed in patients who had local recurrence versus patients without local recurrence. Multivariate analysis further verified that the pre-operative level of MDSC was significantly associated with local recurrence (P=0.038). Therefore, our results indicate that pre-operative percentage of MDSC appears to be a reliable prognostic marker for local recurrence and poor disease free survival in rectal cancer patients with curative resection.
Rectal cancer is the fifth most common malignant tumor in adults worldwide [1] . Although the clinical management for rectal cancer has become increasingly multi-modal, surgery remains a cornerstone curative therapy in rectal cancer [2, 3] . However, surgery can have detrimental effects on patient's physical and psychological well-being at the same time to eradicate the tumor by the greatest extent. Therefore, exploring novel therapies in combination with surgery is of benefit to clinical care of rectal cancer patients.
The prognosis of rectal cancer depends strongly on clinical stage upon diagnosis, although this is not the sole determinant of treatment. Recently, it has been reported that components of the immune system can influence cancer patient outcome [4, 5] .
Myeloid-derived suppressor cells (MDSC), as important regulatory immune cells, play a significant role in the development of immune tolerance in progression of cancer [6] . In addition, it has been reported that MDSC are also associated with autoimmunity and inflammation [7] . MDSC are a heterogeneous population of myeloid origin cells with the ability to suppress T cells [8] [9] [10] . In humans, MDSCs are most commonly defined as express the common myeloid marker CD33 + CD14 -CD11b + cells but lack the expression of markers of mature myeloid and lymphoid cells, and lack the expression of the MHC-class-II molecule HLA-DR [11, 12] . While suppressive myeloid cells were first described more than 20 years ago in cancer patients [13] [14] [15] , the clinical significance of MDSC in human malignancies is still poorly understood.
In this study, a population of Lin -HLA-DR -CD33 + CD11b + cells were readily detected in fresh whole blood and defined as MDSC. We examined circulating MDSC in rectal cancer patients before and after tumor resection, and further studied the association of pre-operative and post-operative circulating MDSC percentages with tumor stage, metastasis, recurrence, and disease-free survival. Prior to surgery, cancer patients were presented with higher levels of circulating MDSC compared to healthy controls, circulating MDSC levels correlate with cancer stage, tumor volume, local recurrence, there was a transient surges in MDSC after tumor resection, then showed a downtrend. Multivariate analysis further verified that the pre-operative level of MDSC appears to be a good prognostic marker for local recurrence and poor disease free survival in rectal cancer patients with curative resection.
Patients and methods
Ethics statement. This study was approved by The Institute Ethical Committee of The Affiliated Cancer Hospital of Zhengzhou University, China. Written informed consents were obtained from all patients.
Patients.
Patients receiving other therapies such as chemotherapy and/or radiotherapy prior to surgery and patients lacking post-operative follow up were excluded from this study. Sixty-four patients were qualified and enrolled in this study. All patients with primary rectal cancer were operated on between January 2008 and December 2008 at the Department of Surgery, The Affiliated Cancer Hospital of Zhengzhou University, China. Whole blood samples were collected from each patient before and after operation. The clinical stage was classified according to the American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition (2010). The median age of patients in this study was 62 years (range 38 -76 years). Thirty-four healthy donors with similar gender and age distribution served as controls (median age 58.7 years). The following clinicopathological characteristics were recorded: age, sex, weight loss, histological grade, carcinoembryonic antigen (CEA) level, smoking status at the time of blood sample collection, and subsequent systemic treatment (Table 1) .
Flow cytometry for myeloid-derived suppressor cells. Fresh venous blood was collected from patients or healthy donors with a heparin sodium anticoagulation tube and used for quantitative MDSC study. For in vitro functional MDSC study, peripheral blood mononuclear cells (PBMC) from fresh venous blood were used. Percentages of circulating HLA-DR -Lin -CD33 + CD11b + MDSC were determined using flow cytometry. Blood samples were collected at one day before operation (BL), and after operation (day 7, day 14, and day 21 after operation). Specific antibodies against Lineage-FITC (Biolegend), HLA-DR-PerCP-cy5.5 (BD Pharmingen™), CD33-PE (BD Pharmingen™), CD11b/Mac-1-APC (BD Pharmingen™) were used. Fresh venous blood samples labeled with corresponding fluorochrome conjugated non-immune isotypes were taken as negative controls. Briefly, 30 μL of blood was mixed with 5 μL of each antibody and was incubated on ice for 20 min in dark. After incubation, each sample was mixed with 2 mL of 1X lysis buffer (BD Biosciences) and incubated at room temperature for 15 min. Samples were washed with FACS buffer (5% BSA in PBS, 0.09% sodium azide), and then fixed with 1% formalin at room temperature for 20 min before washed with FACS buffer again. The pellets were resuspended in 300 μL of FACS buffer and stored at 4°C until analysis. Flow cytometry was performed with a BD FACS Aria II flow cytometer and data were analyzed with FlowJo software.
In vitro suppression assay. PBMC from five healthy donors and five patients with stage III rectal cancer were isolated by Ficoll density gradient from 20 mL of whole blood. HLA-DR Elisa. Plasma arginase I serum levels in cancer patients (N=64, pre-and post-operation) and healthy donors (N=34) were analyzed using an enzyme-linked immunosorbent assay (ELISA) kit (BioVendor, UK). Hemolyzed samples were excluded. All serum samples were assayed in duplicate and the mean absorbance was calculated from the standard curve. In order to measure the levels of arginase activity from isolated HLA-DR -Lin -CD33 + CD11b + MDSC, PBMC were isolated from 20 mL of whole blood taken from 10 healthy donors and 10 rectal cancer patients with stage III at different time points in their course and frozen in liquid nitrogen in a medium of 90% human AB serum plus 10% dimethylsulfoxide. Frozen PBMC were recovered and cultured in a culture medium of RPMI 1640 plus 10% human AB serum (Gibco, Life technologies, USA) for 24 hours before MDSC were sorted and cultured in a culture medium without any stimulation for 48hrs. Then supernatants were harvested for arginase activity investigation with the quanti-chrom arginase assay kit (BioAssay Systems, Hayward, CA) [10] .
Nitric oxide (NO) production. NO content in plasma was measured following the manufacturer's protocol (Biovision, Milpitas, CA, USA). NO content in the culture supernatants from isolated MDSC of 10 healthy donors and 10 patients were also measured. An equal volume of plasma or supernatant (100 μL) and Greiss reagent were mixed and incubated at room temperature for 10 min. Absorbance at 550 nm was measured using a microplate reader (Bio-Rad, Hercules, CA). Nitrite concentrations were calculated from a standard curve generated with serial dilution of 0.25 mM sodium nitrite [10, 16] .
Statistical analysis. Continuous variables were summarized as medians and ranges. Correlation between circulating MDSC percentages and clinicopathological features were examined by the Mann Whitney U test. Spearman's rank correlation coefficiency was used to compare ordinal and continuous variables. Differences in pre-and post-operative circulating MDSC percentages were examined by the Friedman and Kendall test. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. Univariate and multivariate analyses were performed based on the Cox proportional hazards regression model. Survival was determined from the period of surgical operation to occurrence of death / relapse or the last follow-up date. For all analyses of survival, the cut off value for definition of subgroups was the median value. Statistical significance in this study was set as P< 0.05. All reported P-values were performed as two-sided and analyses were performed with SPSS statistical package (SPSS version 13.0 for Windows). + HLA-DR -Lin -cells. The percentage of circulating MDSC was examined in all of the 64 patients before operation. The median percentage of circulating MDSC was 3.89% (range: 0.87% to 9.22%), which was statistically higher than that in healthy controls (median=0.57%, range: 0.32% to 1.21%), P<0.0001, Fig. 1A . The association of MDSC percentage with clinicopathological parameters was further analyzed in cancer patients. There was no significant correlation between MDSC percentage and histological grade (P=0.2547, Fig. 1B ). However, a significant increase of MDSC percentage was observed in stage III patients compared to stage I /II patients (Fig. 1C) , albeit there was MDSC percentage overlap between the two groups of patients. The median percentage of MDSC was 3.56% (range: 0.87% to 5.22%) in stage I/II patients, whereas the median percentage was 4.56% (range: 1.58% to 9.22%) in stage III patients, P=0.0005. In addition, it was also discovered that the MDSC percentages were positively correlated with tumor volume (P<0.0001, Fig.1D ).
Results

Association
Tumor resection causes dramatic transient increase in MDSC. MDSC percentages were determined in all patients at the time of both pre-operation and post-operation. The median MDSC detection rates were 3.89% (range: 0.87% to 9.22%), 7.1% (range: 2.34% to 14.34%), 4.39% (range: 1.89% to 7.32%), and 2.21% (range: 0.56% to 4.24%) at one day before operation (BL) and day 7, day 14, and day 21 after surgery, respectively. There was a dramatic increase in MDSC detection at day 7 after operation, and then decreased at day 14 and day 21 (Fig. 1E ). This represents a 1.83-fold increase in the proportion of circulating MDSC at day 7 after operation compared to BL. The circulating MDSC percentages in patients at day 7 after operation were significantly higher than that before operation, P<0.0001. Representative MDSC flow diagrams from one healthy donor and a patient from whole blood at different time after surgery are shown in Fig. 2 .
MDSC from rectal cancer patients suppress T cell activity. Due to the phenotypic heterogeneity of MDSC, it is essential to characterize their immune-suppressive activity in patients. Representative flow diagrams from one healthy donor and a patient of MDSC in PBMC at different time after surgery are shown in Fig. 2A [20] .
MDSC percentages are positively associated with arginase activity. Next, the mechanism of MDSC-mediated T cell suppression in rectal cancer patients was investigated. Larginine metabolism and its metabolic products are essential for immune-suppressive function of MDSC in cancer-bearing hosts. We investigated the levels of arginase I and NO in peripheral blood samples from rectal cancer patients and healthy donors. There was a significant increase in arginase I levels in rectal cancer patients before surgery as compared with those from healthy controls (P=0.0003). There was a transient increase in arginase I levels in cancer patients after surgery, followed by a decreasing trend (P=0.0004). Plasma NO content was decreased in rectal cancer patients compared to healthy controls. We observe a transient decrease of NO in cancer patients after operation, followed by gradual increase (P<0.0001). In addition, MDSC percentage was positively correlated with arginase I detection(r=0.8026, P<0.0001 at baseline, r=0.7134, P<0.0001 at day 7 after surgery). The mean pre-operative CEA was 8.56 ±7.2 ng/ml (median, 8.76 ng/ml; ranging from 2.43 to 29 ng/ml), which is higher than that in the controls (P<0.0001). To further explore whether there was MDSC qualitative difference in patients' disease course, levels of arginase activity and NO in isolated MDSC cell culture supernatants at different time points were measured. As shown in Fig. 3 , the arginase activity in isolated MDSC from patients is higher than that from healthy donors ( Fig  3A, P=0.0016) , the arginase activity at day 7 after surgery is higher than that before surgery (baseline, Fig 3B, P=0.0048) , and thereafter a downtrend is shown. MDSC percentages at baseline were positively correlated with arginase activity (r=0.8182, P=0.0058, Fig. 3C ), and the MDSC percentages at day 7 after surgery were also positively correlated with arginase activity (r=0.8024, P=0.0073, Fig. 3D ). In contrary to this, NO content in isolated MDSC in healthy donors is higher than that in patients (Fig. 3E) . The intracellular NO content at day 7 after surgery is lower than that before sur- Circulating MDSC percentages correlate with local recurrence. Seven (10.9%), 15 (23.4%), and 22 (34.4%) of the 64 cancer patients had local recurrence at the time of 1 yr, 2 yrs, and 3 yrs after surgery, respectively. It is discovered in this study that MDSC percentage was slightly higher in patients who recurred 1 year after operation, but the difference was not statistically significant (Fig. 4A ). An increase of MDSC percentage at day 21 after operation was also observed in recurrent patients compared to non-recurrence patients (Fig. 4B,  2 .39% versus 1.78%, P=0.0393). The pre-operative percentage of MDSC in patients with local recurrence was significantly higher than that in non-recurrent patients (Fig. 4C, 4 .22% versus 3.78%, P=0.0323). Fourteen of the 31 patients (45.16%) with elevated pre-operative MDSC had local recurrence at the time of analysis, while only 8 of the 33 patients with lower preoperative percentage of MDSC (24.24%) had local recurrence (median 3.89% was used as cut off value). In addition, 13 of the 28 patients (46.43%) with elevated post-operative percentages of MDSC had local recurrence at the time of analysis, whereas there were only 9 patients (25%) developed local recurrence in those 36 patients with lower post-operative percentages of MDSC (median 2.21% was used as cut off value).
We next analyzed the correlation between the MDSC level and distant metastasis. Seven out of the 64 (10.9%) cases had distant metastasis at the time of analysis. MDSC percentage is an independent prognostic factor in rectal cancer. To examine whether MDSC percentage could be a prognostic indicator, the 64 patients were divided into two groups by cutoff value based on median percentage. Four of the 64 (6.25%) cancer patients died at the time of analysis. Median follow-up for remaining patients was 42 months (ranging from 10 to 47 months). Patients with high MDSC percentage at baseline had lower disease-free survival (DFS) compared to the patients with low MDSC percentage (P=0.0357, Fig. 4F ), and patients with high MDSC percentage at day 21 had lower DFS compared to the patients with low MDSC percentage at day 21(P=0.0460, Fig. 4G ). In addition, patients with high MDSC percentage at baseline had lower local recurrence free survival compared to the patients with low MDSC percentage at baseline (P=0.0368, Fig. 4H ), and patients with high MDSC percentage at day 21 had lower local recurrence free survival compared to the patients at day 21 with low MDSC percentage (P=0.0427, Fig. 4I ). Next we analyzed the correlation between clinicopathological parameters and DFS. As shown in Table 2 , pre-operative MDSC percentage (P=0.038) and CEA (P=0.012) were all significantly associated with poor DFS. The MDSC percentage was strongly associated with local recurrence (P=0.038). There was no evidence that tumor grade, post-operative complications, or subsequent treatment status had any impact on local tumor recurrence in our experimental cohort. 
Discussion
MDSC are a heterogeneous population of myeloid cell origin capable of inhibiting adaptive and innate immunity [21] . In healthy subjects, MDSC differentiate into dendritic cells, macrophages and granulocytes. MDSC content is elevated under chronic inflammatory conditions such as stress, aging, infections, cancer or autoimmunity [22] . Most of the recent studies suggest that two major human MDSC subsets exist: granulocytic-MDSC and monocytic MDSC [23] . However, standardized and generally accepted immunophenotyping scheme allows for a clear discrimination of human MDSC subsets is currently missing. The levels of general HLA-DR 
CD11b
+ MDSC were analyzed in our study.
MDSC have been reported to be correlated with clinical cancer stage, metastatic tumor burden, and chemotherapy resistance [24, 25] . Gabitass et al. have recently reported that an elevated level of circulating MDSC in pancreatic, esophageal, and gastric cancers is an independent prognostic factor for survival [26] . In this study, we report significantly higher percentage of circulating MDSC in rectal cancer patients than in normal volunteer subjects. Furthermore, significantly higher percentage of MDSC was observed in clinical stage III patients than in the stage I/II patients. However, apparent MDSC percentage overlap was seen in these two groups of patients. This may be explained by tumor burden correlation of MDSC content. As we observed in these patients, MDSC percentage is positively associated with tumor volume. How- ever, it is known as disclosed in the "Staging manual of AJCC and the response evaluation criteria in solid tumors (RECIST 1.1)" [27] that patients in stage I/II may have the similar tumor burden with some stage III patients. The relative content of MDSC detection is higher in our study compared to the previous report [28] . Despite the difference in sample collecting methods, our results are largely in line with these reports. Recently, Zhang B, et.al. [19] investigated tumor infiltrating MDSC in colorectal carcinoma, and found significantly higher percentage and absolute number of tumor-infiltrating MDSC compared with those in matched non-cancerous tissues. It is interesting to know whether circulating MDSC are associated with tumor infiltrating MDSC. Theoretically, tumor infiltrating MDSC may have rather direct clinical consequences since these cells will influence the microenvironment of tumor cells. Therefore, clinical influence of tumor infiltrating MDSC in rectal carcinoma merits further studies.
In Ohki's study [29] , the content of circulating MDSC was lower in breast cancer patients after surgery compared to pre-operation subjects, but the exact post-operation date was not reported. Zhu et al [30] used a mouse model to show that surgery induced myeloid cells to MDSC with higher levels of arginase I, an enzyme which depletes arginine. In our study, the most interesting finding is that there was a dramatic MDSC increase in the rectal cancer patients after surgery, and then the MDSC content was gradually reduced, indicating that MDSC induction by surgery [31, 32] may be an early event in the post-operation period. This could be explained as following. First, surgical stress induces expansion of MDSC [31] . Tai et al observed an approximately 2.5-fold increase in the proportion of spleen MDSC after surgery compared to non-surgery controls. In our study, about 1.8-fold increase of circulating MDSC was observed on day 7 after surgery compared to the pre-operative percentage. Second, psychological stress is associated with altered MDSC content [32] .. Third, surgery generally induces physical trauma to patients resulting in inflammations such as aseptic inflammation and/or bacterial inflammation during the perioperative period. It has been demonstrated that inflammation could increase apoptosis resistance in MDSC [33] [34] [35] . The massive expansion of MDSC after operation indicates that MDSC are poised to be excellent sentinels against infection in the face of systemic stress. In addition, the body secretes many inflammatory cytokines after surgery leading to an immune activation in post-operation individuals. Therefore, inflammatory response may be an alternative mechanism for MDSC expansion in rectal cancer patients.
MDSC exert their immunosuppressive activity through multiple mechanisms [15, 17, [35] [36] [37] . In human, arginine is a crucial player in host defense. MDSCs hydrolyze arginine to urea and ornithine with the enzyme arginase, leading to the synthesis of polyamines and proline. In our present study, there was a significant positive correlation between MDSC and arginase I in rectal cancer patients during the period of perioperative.
We also measured the arginase activity and NO levels in the MDSC culture supernatants from MDSC collected at different time points. As we have verified in our present study that arginase activity at day 7 after surgery is significanly higher than that before surgery (baseline), and then gradually reduced. However, NO content in isolated MDSC at day 7 after surgery is lower than that before surgery (baseline). These findings are consistent with the findings for circulating MDSC and NO suggesting that the increased arginase I in MDSC result in depletion of L-arginine, and then NO production in tumors by iNOS metabolization of L-arginine is reduced as well. However, detail molecular mechanism of NO decrease after surgery is still a matter of study. Our in vitro experiment of T-cell suppression verification of tumor MDSC may support the notion that depletion of L-arginine by tumor MDSC plays an important role in immune suppressive function in rectal cancer patients after surgery, although detail molecular mechanism behind this typical tumor MDSC Tcell suppression is to be explored. Many investigators suggest a positive correlation between clinical cancer stage, metastatic tumor burden, and the percentage of MDSC [22, 24, 38, 39] . Elevated MDSC content has been shown to be an independent prognostic factor in some cancers [26] . However, this study shows the difference in pre-and post-operative percentages of circulating MDSC in rectal cancer patients. Local recurrence and survival, the most important endpoints in rectal cancer management [1] , were used as the end points in this study. We show that the percentages of MDSC both before surgery and 21 days after surgery correlate with DFS in patients with rectal cancer in univariate analyses. But in the multivariable model, only pre-operative content of MDSC is an independent factor for DFS in rectal cancer patients. Therefore, our results imply that a strong surgical trauma can result in a transient induction of MDSC caused by the increase in arginase I and then resulted in L-arginine depletion. However, the higher MDSC percentage (median 2.21%, range from 0.56% to 4.24%) observed on day 21 after surgery compared to the normal controls (median 0.57%, ranging from 0.32% to 1.21%) may be due to pathological response to local recurrence and this deserves further investigations. The induction and reduction of MDSC content during early and late post-operations in rectal cancer patients may imply that operation-induced MDSC is reversible, characterizing the clinical significance of MDSC in rectal cancer may provide clues for novel treatment modalities in conjunction with surgical operation.
Alternatively, immune therapy holds promise as a treatment option in perioperative therapy. Understanding the MDSCmediated systemic immune suppression during perioperative period would benefit development of cancer therapeutics and management of adverse side effects.
Supplementary information is available in the online version of the paper. 
